Digestive Remedies in Norway

PROSPECTS

Digestive remedies sees slow growth during 2018

The growth of digestive remedies remained relatively slow in 2018, as in the review period Norwegians substituted several products within digestive remedies with dietary supplements and/or a more holistic way of managing health and wellness. Alternative products included probiotic supplements, which increased quickly during the latter part of the review period, although saw a decline in 2018.

Proton pump inhibitors increasingly substitute H2 blockers

Proton pump inhibitors saw higher sales in 2018 for several reasons, such as the declining availability of H2 blockers and the overall substitution effect of proton pump inhibitors for H2 blockers. This trend is projected to continue unless the new research on the risk of renal failure due to continued use of proton pump inhibitors reaches the mass media and becomes widespread news.

Older Norwegians suffer from digestive problems

Norway is similar to many other Western European countries, particularly Northern European countries, in having an ageing population. Female life expectancy was 85 and male life expectancy 81 in 2018 according to Euromonitor International.

COMPETITIVE LANDSCAPE

Johnson & Johnson Consumer Nordic leads digestive remedies

Johnson & Johnson Consumer Nordic remained the leading company within digestive remedies during 2018, supported by its large brands Pepcid, Imodium and Microlax, which benefited from a strong image built through strong distribution and a long-standing presence in the market. Pepcid also enjoyed rapid growth in sales in 2018, due to the lack of other brands within its product category, H2 blockers.

Rehydration diarrhoeal remedies brands see strong growth during 2018

Norway, similar to most other Northern European countries, saw a strong heatwave in 2018, which lasted for many weeks in the summer. This led to increasing demand for rehydration products such as diarrhoeal remedies with rehydration properties.

Pepcid is the sole player within H2 blockers

Pepcid was the only brand left in H2 blockers during 2018, due to the withdrawal of Ranitidin from PGT Healthcare and Zantac, a brand distributed by GlaxoSmithKline, in 2017. Pepcid therefore saw very strong growth during 2018, despite the overall decline of the category.

Files are delivered directly into your account within a few minutes of purchase.